Filing Flows › BioMarin Pharmaceutical (BMRN) › R&D spending
BioMarin Pharmaceutical (BMRN) R&D spending by quarter
BioMarin Pharmaceutical's R&D spending was $181M in Q3 2026 (third quarter 2026), -13% from Q2 2026. Over the last 7 quarters it ranged from $159M (Q1 2025) to $409M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $181M | -13% | -56% |
| Q2 2026 | $207M | +16% | +28% |
| Q1 2026 | $179M | -7% | +13% |
| Q4 2025 | $192M | -53% | — |
| Q3 2025 | $409M | +154% | — |
| Q2 2025 | $161M | +2% | — |
| Q1 2025 | $159M | — | — |
Q3 2026 at a glance
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Questions
What is BioMarin Pharmaceutical's R&D spending?
BioMarin Pharmaceutical's R&D spending was $181M in Q3 2026 (third quarter 2026), -13% from Q2 2026.
How has BioMarin Pharmaceutical's R&D spending changed?
Over the last 7 quarters it ranged from $159M (Q1 2025) to $409M (Q3 2025).
Q3 2026 results → · How BioMarin Pharmaceutical makes money →